Abstract
We present our experience with pediatric ABO-incompatible liver transplantation in India. Data of patients <18 years of age undergoing ABO-incompatible liver transplantation our hospital between January, 2011 and November, 2018 were analyzed. Plasmapheresis was done pre-transplant till antibody titer was <16 units. Rituximab/Intravenous immunoglobulin was used for immunosuppression, in addition to standard drugs (mycophenolate mofetil, steroids, and tacrolimus). Out of 203 patients that underwent liver transplant during this period, 8 underwent ABO-incompatible liver transplantation; 4 (3 boys) had blood group O+ve. Median (range) age was 28 (7–91) mo, PELD score was 24.5 (14–42), and pre-transplant antibody titer range was 1:32–1024. Number of plasmapheresis sessions required ranged from 1–6. Post-operatively two patients had rise in antibody titer >64 requiring plasmapheresis. All 8 patients survived without rejection/biliary issues. Mean (range) of post-transplant hospital stay was 19.1 (13–22) d and follow-up period was 38.1 (7.1–84.4) mo. Pediatric ABO-incompatible liver transplantation can be successfully performed using plasmapheresis with optimal immune-suppression and vigilant post-op monitoring.
References
Tanabe M, Kawachi S, Obara H, et al. Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest. 2010; 40: 943–9.
Tiwari AK, Pandey P, Aggrawal G, et al. Cascade plasmapheresis as a preconditioning regime in ABO-incompatible live related donor liver transplants. Transplant Res. 2014;3:17.
Raut V, Uemoto S. Management of ABO-incompatible living-donor liver transplantation: Past and present trends. Surg Today. 2011;41:317–22.
Wu J, Ye S, Xu X, Xie H, Zhou L, Zheng S. Recipient outcomes after ABO incompatible liver transplantation: A systematic review and meta-analysis. PLoS One. 2011;6:e16521.
Sanchez-Urdazpal L, Batt KP, Gores GJ, et al. Increased bile duct complications in ABO incompatible liver transplant recipients. Ann Surg. 1993;218:152–8.
Warner PR, Nester TA. ABO-incompatible solid-organ transplantation. Am J Clin Pathol. 2006;125:S87–94.
Kozaki K, Egawa H, Ueda M, et al. The role of apheresis therapy for ABO incompatible living donor liver transplantation: The Kyoto university experience. Ther Apher Dial. 2006;10:441–8.
Pescovitz MD. Rituximab, an anti-20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006; 6: 859–66.
Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology. 2008:47:143–52.
Author information
Authors and Affiliations
Corresponding author
Additional information
Contributors
NM,VR: wrote the manuscript; MD: contributed to design, data compilation and analysis; MD, AT: data compilation and manuscript writing; PB,AS: contributed to the surgical aspects of the manuscript. VR,PB,MD: involved in coordination of the study and revision of the manuscript; NM, AS: final editing of the manuscript. All authors approved the final manuscript.
Funding
None
Competing interests
None stated.
Rights and permissions
About this article
Cite this article
Mohan, N., Raghunathan, V., Dhaliwal, M.S. et al. Pediatric ABO-incompatible Living Related Donor Liver Transplantation: Experience from Indian Subcontinent. Indian Pediatr 58, 281–282 (2021). https://doi.org/10.1007/s13312-021-2172-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-021-2172-z